IRF5 program strengthens Kymera’s oral immunology pipeline with a complementary mechanism to expand into rheumatic and other autoimmune diseases with a potential best-in-class oral drug IRF5, a ...
BOSTON, June 25, 2025 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small molecule allosteric therapies targeting Smart ...
Interferon regulatory factor 5 (IRF5) is a transcription factor activated downstream of Toll-like receptors (TLRs) 7, 8 and 9, and is predominantly expressed in dendritic cells, B cells, monocytes and ...
Good morning and welcome to Kymera's Immunology Innovation Day, our virtual event to introduce our next immunology program, IRF5. I'm Justine Koenigsberg, Kymera's Head of Investor Relations. Please ...
The MarketWatch News Department was not involved in the creation of this content. BOSTON, June 25, 2025 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results